Control Her Treatment…
End Her Pain and Suffering

- Outpatient fibroid therapy
- High patient satisfaction
- Low re-intervention rate
The Acessa Procedure

The Acessa procedure is a new minimally-invasive, same-day (outpatient) therapy for fibroids. It uses a technology called radiofrequency ablation. Each fibroid is destroyed by applying energy through a small needle array. The surrounding normal uterine tissue is not affected. The destroyed tissue may then be completely reabsorbed.

She will prefer this option:
• No Referral
• Limit Rejection of Treatment

She will be happy with the results:
94% Patients were satisfied with the treatment
98% Patients would recommend to a friend
94% Patients responded that the treatment had been effective in eliminating their symptoms

Physicians identify and treat significantly more fibroids:
• Intra-abdominal ultrasound identified 46% more fibroids than MRI and 107% more fibroids than transvaginal ultrasound
• Treated an average of 5 fibroids in each patient

Acessa Generator

The Generator works seamlessly with the Handpiece to provide radiofrequency energy for ablation and traditional electrocautery to control the bleeding common in the treatment of myomas. It provides the surgeon continuous monitoring and real-time temperature control.

Acessa Handpiece and Electrode Array

The Handpiece includes the control feature for generator interface and the Electrode Array. The deployable electrode array allows the treatment of fibroids of varying size. Once the Handpiece is inserted into the myoma, the electrode array is deployed under ultrasound guidance. The duration of the ablation is defined by a treatment algorithm based on the amount of deployment.
Summary of Clinical Results

- **Subject Inclusion Criteria**
  137 women, 25 years of age or older, with clinical menorrhagia, ≤ 6 treatable fibroids, none exceeding 7 cm in diameter, and total uterine fibroid volume not exceeding 300 cc

- **Device-Related Safety**
  The rate of complications for the Acessa System was < 4%

- **Efficacy**
  81% of subjects experienced a reduction of bleeding at 12 months

Please reference product Instructions for Use for more information regarding indications, warnings, precautions, contraindications and adverse events.

<table>
<thead>
<tr>
<th>Description</th>
<th>Model #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acessa Generator</td>
<td>1000</td>
</tr>
<tr>
<td>Acessa Handpiece</td>
<td>2000</td>
</tr>
<tr>
<td>Acessa Pads</td>
<td>3000</td>
</tr>
<tr>
<td>Foot Pedal</td>
<td>4100</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Description</th>
<th>Model #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Power Cord</td>
<td>4110</td>
</tr>
<tr>
<td>Handpiece Cable</td>
<td>4200</td>
</tr>
<tr>
<td>Pad Cable</td>
<td>4300</td>
</tr>
</tbody>
</table>

**Customer Service**

+1-877-412-3828 or customerservice@haltmedical.com

**References**


Halt Fibroid Study, NCT00874029, September 07, 2012 provided by Innovative Analytics, Kalamazoo, MI.